This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).
Age >18 years and<75 years;
Willingness to sample collection, imaging study and other disease-related examinations and assessments;
The results of pregnancy tests for female subjects with fertility during the screening period should be negative and effective contraception was used by the patient and her spouse during the study period;
Patients with informed consent;
History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue;
Patients who may have other diseases that may lead to eyelid drooping, peripheral muscle weakness or diplopia;
Age ≤18 years or ≥75 years;
Patients who have been taking glucocorticoids or associated immunosuppressants due to other immune system diseases;